Precision BioSciences Inc. (DTIL)
DTIL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$6.10
-6.58% on the day
Market cap
$168.4M
Micro cap
Revenue · 2025
$34.3M
-50.1% on 2024
Net income · 2025
-$45.7M
-133.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | DTIL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001357874 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $34.3M |
| Net income | -$45.7M |
| Operating income | -$52.1M |
| Net margin | -133.4% |
| Operating margin | -152.2% |
| Revenue growth | -50.1% |
| Cash | $110.8M |
| Total assets | $154.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-12-30 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-24 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 597 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CHRS | Coherus Oncology Inc. | $1.07 | +3.88% | $165.3M |
| IPHA | Innate Pharma S.A. ADS | $1.47 | -0.68% | $164.2M |
| STRO | Sutro Biopharma Inc. | $11.01 | -17.09% | $182.6M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
| CGEN | Compugen Ltd. | $1.98 | -4.35% | $187.3M |
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier